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Abstract
Prostate cancer (PCa), a leading cause of cancer-related morbidity and mortality, arises throughand epigenetic alterations. Deregulation of histone methyltransferases (HMTs) or demethylases
with PCa development and progression. However, the precise influence of altered HMTs or HDM
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in men from developed countries and a leading cause of 
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(Stamey 1995). However, prost the acquisition of genetic 
 (HDMs) has been associated s expression and respective histone marks in PCa onset and progression remains largely unknown. To clarify the role of HMTs and HDMs in prostate carcinogenesis, expression levels of 37 HMTs and 20 HDMs were assessed in normal prostate and PCa tissue samples by RT-omatic low-stage tumors, 
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(MLL1-5) and KDM4B were downregulated in PCa, compared with normal prostate tissues. R
histone modifier that best discriminated normal from tumorous tissue samples. Interestingly
levels significantly correlated with less differentiated and more aggressive tumors. Remarkab
were of independent prognostic value for the prediction of disease-specific survival of PCa p
disease submitted to radical prostatectomy. We concluded that expression profiling of HMTs
might be of clinical usefulness for the assessment of PCa patients and assist in pre-therapeuti
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cancer-related morbidity and mortality worldwide (Jemal 
et al. 2011, Siegel et al. 2012). At its earliest stages, PCa is 
frequently asymptomatic, fostering the use of biomarkers, 
limitations, including sampling error as well as intra- and
interobserver variability in Gleason grading (King & Long
2000, Allsbrook et al. 2001), which even in conjunctionwithsuch as serum prostate-specific antigen (PSA), for screening
other prognostic factors used for therapeutic decision (e.g.,
clinical stage andpre-therapeutic serumPSA levels) are rather
imperfect in predicting disease progression (Lapointe et al.
2004,Duffy2011).Consequently, there is a significantdegree
of uncertainty concerning the threat that a PCa poses to an
individual patient, entailing overtreatment (Moyer 2012).
The role of epigenetic modifications in cancer
initiation and progression has been emphasized (Hirst &
Marra 2009). In addition to aberrant DNA methylation,
alterations in chromatin modification patterns, due to
histones post-translational modifications (PTMs), were
implicated in carcinogenesis and have emerged as
potential key regulators of cancer-related pathways
(Miremadi et al. 2007). Importantly, PTMsmay be changed
in cancer cells due to altered expression or activity of key
chromatin-modifying enzymes (Miremadi et al. 2007).
Histone methylation, carried out by histone methyl-
transferases (HMTs), requires different families of enzymes
depending on the residue (lysine HMTs (KMT) methylate
lysine residues, whereas protein arginine methyltrans-
ferase (PRMT) methylate arginines) and might positively
or negatively regulate gene transcription. Although lysine
residues might be modified into mono-, di-, or trimethyl
states, arginine can only bemodified tomono- or dimethyl
states (symmetric or asymmetrically) (Brame et al. 2004).
Different degrees of methylation may be, thus, associated
with distinct chromatin regions or transcriptional states
(e.g., trimethylation of lysine 9 of histone H3 is associated
with pericentromeric heterochromatin and transcriptional
repression, whereas its dimethylation is linked to repressed
genes in euchromatin (Lee et al. 2006)). Recently, the
reversibility of histone methylation has been established
through the discovery of histone lysine and arginine
demethylases (HDMs), uncovering a new level of histone
plasticity (Shi et al. 2004, Chang et al. 2007).
AlteredHMTsexpression levels havebeen found inPCa,
most notably enhancer of zeste homolog 2 (EZH2), a lysine
methyltransferase, which is increased in metastatic PCa,
marking aggressive disease (Seligson et al. 2005, Karanikolas
et al. 2010). Specific relationships between histone marks
and tumor grade or recurrence (particularly methylation of
H3K4 and H3K27) have been reported (Seligson et al. 2009,
Bianco-Miotto et al. 2010) and deregulation of some lysine
HMTs – KMT2B, KMT2C, NSD1, EZH2 or SMYD3 – in PCa
tissues has been also demonstrated (Ke et al. 2009,
Bianco-Miotto et al. 2010). However, the validity of most
studies is limited due to inappropriate tissue sampling
and/or to the reduced number of samples tested.
Because deregulation of HMTs and HDMs affects
post-translational control of cellular proteins involved incancer-relevant signaling networks, a better understand-
ing of their function might lead to the identification of
more accurate markers that might be useful to discrimi-
nate patients benefiting from a more aggressive treatment
from those that might be spared unnecessary and
potentially harmful interventions. Therefore, we sought
to identify HMTs and HDMs displaying altered expression
levels, in a relatively large series of PCa patients submitted
to radical prostatectomy, and further test their clinical
usefulness for the prediction of disease progression.Materials and methods
Patients and tissue collection
Primary tumors from 160 patients with clinically
localized prostate adenocarcinoma, consecutively
diagnosed, and primarily treated with radical prosta-
tectomy at the Portuguese Oncology Institute, Porto,
Portugal, were prospectively collected. For control
purposes, non-neoplastic prostate tissue samples were
obtained from the peripheral zone of 15 prostates not
harboring PCa collected from cystoprostatectomy
specimens of patientswithbladder cancer (normal prostate
tissue (NPT)). All tissue specimens were promptly frozen
immediately after surgery, following informed consent.
Five-micron thick sections were cut and stained for the
identification of the areas of PCa (i.e., the index or
dominant tumor) and normal tissue. Then, the tissue
block was trimmed to maximize the yield of target cells
(O70% of target cells). Subsequently, an average of fifty
12-mm thick sections was cut and every fifth section was
stained to ensure auniformpercentage of target cells and to
exclude contamination from neoplastic cells in normal
tissue samples. Histological slides from formalin-fixed,
paraffin embedded tissue fragments were routinely
obtained from the same surgical specimens and assessed
forGleason score (GS; Gleason&Mellinger 1974) andTNM
stage (Hermanek et al. 1997). Relevant clinical data were
collected from the clinical records. These studies were
approved by the institutional review board (Comissa˜o de
E´tica para a Sau´de-(IRB-CES-IPOFG-EPE 019/08)) of
Portuguese Oncology Institute, Porto, Portugal.RNA isolation
All tissue samples were suspended in TRIzol reagent
(Invitrogen) and, after addition of chloroform to the lysed
cells, total RNA was purified from the aqueous phase of
TRIzol extract using the PureLink RNAMini Kit (Invitrogen)
following manufacturer recommendations. The concen-
tration, purity, and integrity of RNA samples were
determined on a Nanodrop ND-1000 (ThermoScientific,
Wilmington, DE, USA) and agarose-gel electrophoresis.Screening of HMTs and HDMs
Five NPTs and ten independent PCa samples were chosen to
encompass the full spectrum of prostate carcinomas in this
series considering the GS and pathological stage (Table 1).
After treatment with DNase Turbo DNA-free (Ambion,
Austin, TX, USA), a total of 1 mg total RNA was reverse
transcribed using the High Capacity cDNA RT kit (Applied
Biosystems) according to the manufacturer’s instructions.
TaqMan Array 96-Well Plates were designed in order to
evaluate expression levels of 37 HMTs and 20 HDMs.
RT-qPCR protocol was performed on an ABI- 7500 Real-
Time PCR system (Applied Biosystems) according to manu-
facturer’s instructions and each sample was run in triplicate.
The amount of mRNAs of the genes studied was
normalized to that of the GUSB reference gene and the
median value of NPTs and PCa samples was chosen to
calculate fold-difference ingene expressionbetween groups,
using the comparative Ct method. Genes with a logarith-
mized fold change above 0.5 or below K0.5 were further
considered. The expression of KDM6A was also included
because it has been previously reported as deregulated in
several tumormodels (vanHaaften et al. 2009), and analysis
was extend to all members of the KMT2 family.Validation of selected enzymes
After gene selection, mRNA levels were confirmed in
a large and independent group of 150 PCa tissues andTable 1 Clinical and pathological features of patients inclu
PCa No
Number of patients, n 10
Age (years), median
(range)
59 (53–71) 61 (4
PSA levels (ng/ml),
median (range)
12.3 (3.5–19.9) N
Pathological stage, n (%) N
pT2 4 (40.0)
pT3a 2 (20.0)
pT3b 4 (40.0)
Gleason score, n (%) N
!7 3 (30.0)
R7 7 (70.0)
PCa, prostate cancer; NA, not applicable.15 NPTs. A total of 300 ng was reverse transcribed and
amplified using TransPlex Whole Transcriptome Amplifi-
cation Kit (Sigma–Aldrich) with subsequent purification
using QIAquick PCR Purification Kit (Qiagen), according
to manufacturer’s instructions. HMTs or HDMs mRNA
levels were evaluated using TaqMan Gene Expression
Assays (Applied Biosystems, Supplementary Table 1, see
section on supplementary data given at the end of this
article) and the most suitable endogenous control assays
for the analysis of prostate tissues (de Kok et al. 2005),
GUSB, and TFRC were also analyzed. To determine the
relative expression levels in each sample, the values of the
target gene were normalized using the median of the two
internal reference genes to obtain a ratio (HMT or
HDM/Mean of TFRC and GUSB). Each plate included
multiple non-template controls and serial dilutions of a
cDNA from human prostate RNA (Ambion, Invitrogen) to
construct a standard curve for each plate. All experiments
were run in triplicate.Statistical analysis
For statistical analysis purposes, PCa samples were divided
into two- or three-grade categories for GS (GS %6 and GS
R7) and pathological stage (pT2, pT3a, and pT3b)
respectively. The Shapiro–Wilk’s W-test allowed for the
examination of the appropriateness of a normal
distribution assumption for each of the parameters (data
not shown). Then, the median and range of the mRNA
expression levels for each group of samples were
determined and analyzed using Mann–Whitney U test.
A receiver operator characteristics (ROC) curve was
constructed by plotting the true positive rate (sensitivity)
against the false positive rate (1-specificity) and the areaded in the testing set and in the validation series
rmal PCa Normal
5 150 15
9–66) 64 (49–75) 64 (45–80)
A 8.2 (2.9–23.0) NA
A NA
89 (59.3)
50 (33.3)
11 (7.3)
A NA
57 (38.7)
93 (62.0)
under the curve (AUC) was calculated to assess diagnostic
performance. Possible correlations between the expression
levels and GS or pathological stage were assessed by
the Kruskal–Wallis one-way ANOVA, followed by
Mann–Whitney U test when appropriate. For multiple
comparisons, the Bonferroni method was used to adjust
P values. Spearman nonparametric correlation tests were
additionally carried out to ascertain correlations between
age, PSA levels, and HMTs or HDMs expression levels. The
prognostic significance of available clinical variables
(pathological stage, GS, age, and serum PSA levels) was
assessed by constructing disease-specific and disease-free
survival (DFS) curves using the Kaplan–Meier method with
log-rank test (univariate test). A Cox-regression model
comprising the four variables (multivariate test) was also
constructed. DFS was calculated from the date of the
radical prostatectomy to the date of biochemical relapse, or
date of last follow-up, or death if relapse-free. For the
purposes of survival analyses, all cases were coded based on
the expression levels of each enzyme using the percentile
75 value as empirical threshold. Cases were also subdivided
according to serum PSA levels (below and above median
values) and age (above 60, between 60 and 70, and above
70). Statistical analysis was performed using SPSS for
Windows, version 20.0 (SPSS) and the level of significance
was set to P!0.05. Graphs were built using GraphPad
Prism 5.0 software for Windows (GraphPad Software, Inc.,
La Jolla, CA, USA).Results
Evaluation of HMTs and HDMs expression levels
Expression levels of 37 HMTs and 20 HDMs were assessed
in ten PCa and five normal prostate samples (relevant
clinical and pathological data are depicted in Table 1).
Most enzymes were downregulated in PCa compared with
NPT (Fig. 1). Based on fold-variation, lysine HMTs
SUV39H2, SMYD3, KMT2A-E, and EZH2 (the latter used as
positive control according to the literature); argine HMT
PRMT6; and HDMs KDM4B, KDM6A, KDM5A, and KDM3B
were selected for validation (Supplementary Table 2, see
section on supplementary data given at the end of this
article). This was performed using RT-qPCR in a larger and
independent series comprising 150 PCa samples and
15 NPTs (relevant clinical and histopathological data are
displayed in Table 1). Statistically significant differences
between NPT and PCa tissue samples were found for all
candidate genes, except KDM3B (Table 2). As expected,
higher EZH2 expression levels were observed in PCacompared with NPT and the same trend was verified for
SMYD3, SUV39H2,PRMT6,KDM5A, andKDM6A (Fig. 2 and
Table 2). Contrarily, all selected members of KMT2 family
andKDM4Bwere downregulated in PCa samples compared
with NPT (Fig. 3 and Table 2). Interestingly, significant
positive correlations between several members of KMT2
family were found in PCa samples (Table 3). To reinforce
the oncogenic role of altered enzyme expression, transcript
levels (categorized according to percentile 75) were tested
as PCa biomarkers in tissue samples. Remarkably, PRMT6
performed best in sensitivity (90.0%) and specificity
(73.3%) for discriminating PCa from NPT, and ROC curve
analysis showed an AUC of 0.923 (95% CI 0.870–0.977,
P!0.001) (Fig. 4). No significant differences in age between
PCa patients and normal tissue donors were apparent.
Statistically significant associations between expression
levels of SMYD3 (PZ0.044) or KMT2A (PZ0.041) and
pathological stage were disclosed (higher levels in pT3b
cases for both genes, Fig. 5A and B). When the patient
cohort was stratified according to GS, increased levels of
EZH2 (PZ0.048) and KMT2C (PZ0.018) were associated
with less differentiated tumors (Fig. 5C and D). No
statistically significant associations were found between
gene expression levels and patients’ age or PSA levels.Survival analysis
The median follow-up period of this series of PCa patients
was 105 months (range: 3–145 months). At the time of the
last follow-up, five patients (3.3%) had died from PCa and
45 of 136 (33%) presented biochemical recurrence. In 14
patients, serum PSA levelsO0.2 ng/ml persisted following
surgery and these were not further considered for DFS
analysis. Disease-specific survival curves using established
clinical variables or expression levels of selected genes
did not display prognostic value within the available
follow-up time. However, DFS analysis showed that
tumors with higher transcript levels of EZH2 (PZ0.001)
or SMYD3 (PZ0.010) were significantly associated with a
shorter time to relapse, in a univariate analysis (Fig. 6).
Higher GS (P!0.001), advanced pathological stage (pT3a
PZ0.016 and pT3b PZ0.002), and higher PSA levels
(PZ0.029) were also associated with shorter DFS, whereas
agewas not of prognostic valuewithin the available follow-
up time. In multivariate analysis, higher GS, stage pT3b,
and high SMYD3 expression levels retained statistical
significance (PZ0.001, PZ0.027, and PZ0.025
respectively) and were capable of predicting prognosis
independently, whereas EZH2 expression, PSA, and
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Figure 1
Expression levels of 37 HMTs and 20 HDMs in normal and PCa tissues. Gene expression of five normal prostate tissues and ten PCa calculated using
comparative Ct method. The results presented correspond to median value of each group.pathological stage pT3a did not show independent
prognostic value, in this dataset (Table 4).Discussion
Deregulation of histone PTM patterns has been associated
with PCa development and progression (Seligson et al.
2005, Ke et al. 2009, Bianco-Miotto et al. 2010). Because
these modifications might be due to altered expression or
activity of key chromatin-modifying enzymes (Miremadiet al. 2007), we attempted to globally characterize
alterations in expression affecting HMTs and HDMs in
PCa tissues and determine whether those might be of
clinical and pathological relevance.
Overall, 37 HMTs and 20 HDMs expression levels were
assessed, comprisingmost of the relevantmembers of each
class. Owing to the relatively large number of genes tested,
this panel was initially tested in a small series of tissue
samples. This might underestimate the frequency and
magnitude of changes in gene expression, but it allows for
Table 2 Distribution of selected HMTs and HDMs expression levels in normal and PCa tissue samples
Gene Normal Tumor P value, M–W AUC
EZH2 0.77 (0.39–1.82) 1.15 (0.09–4.85) 0.014 0.692
KMT2A 0.69 (0.21–2.52) 0.29 (0.08–1.30) !0.001 0.212
KMT2B 3.23 (1.61–6.76) 2.05 (0.49–8.07) 0.004 0.272
KMT2C 2.37 (1.24–4.40) 1.45 (0.39–4.06) !0.001 0.232
KMT2D 3.91 (1.36–10.21) 1.97 (0.36–8.66) !0.001 0.272
KMT2E 0.73 (0.58–3.46) 0.53 (0.21–1.55) !0.001 0.162
PRMT6 0.16 (0.02–0.30) 0.43 (0.10–1.77) !0.001 0.923
SMYD3 0.90 (0.53–1.44) 1.53 (0.53–4.50) !0.001 0.855
SUV39H2 1.07 (0.63–2.48) 1.36 (0.32–3.43) 0.044 0.657
KDM3B 0.26 (0.03–0.45) 0.24 (0.11–0.78) NS 0.495
KDM4B 2.24 (0.47–7.81) 0.47 (0.08–2.23) !0.001 0.098
KDM5A 0.21 (0.10–0.63) 0.32 (0.07–0.77) 0.026 0.675
KDM6A 0.33 (0.03–0.52) 0.47 (0.20–1.58) !0.001 0.813
HMT, histone methyltransferase; HDM, histone demethylase; PCa, prostate cancer; M–W, Mann–Whitney U test; AUC, area
under the curve; NS, not significant.the selection of the most significantly altered. Thus, to
confirm the initial findings in the arrays, a validation
study was performed for the selected genes using RT-qPCR
and only three out of 12 genes were not confirmed.
Importantly, genes that were previously reported to be
overexpressed in PCa, such as EZH2 (Karanikolas et al.
2010), surfaced in the array and were confirmed in the
large series of PCa, thus validating our initial approach.
Furthermore, EZH2 expression was significantly increased6.0A B
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Identification of HMTs and HDMs overexpressed in PCa. Relative quantification
(F), displaying higher expression levels in PCa compared with normal prostatein high GS cases, not associating with pathological stage,
confirming previous observations (Laitinen et al. 2008).
Interestingly, some of the most significantly altered
genes encode for enzymes that display antagonistic
functions. Although this might result in a balance bet-
ween repressive and active PTMs, it must be recalled that
the effect in gene expression will depend on the specific
genomic locations and how tumor suppressor genes
or oncogenes are differentially affected (Hake et al. 2004,C
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Figure 3
Identification of HMTs and HDMs downregulated in PCa. Relative quantification of KMT2A (A), KMT2B (B), KMT2C (C), KMT2D (D), KMT2E (E), and
KDM4B (F) depicted lower levels in PCa compared with normal prostate tissues (****P!0.0001; ***P!0.001; **P!0.01).
Table 3 Coefficient of correlation (r) between the expression
levels of all members of KMT2 family in PCa tissue samples
KMT2A KMT2B KMT2C KMT2D KMT2E
KMT2A – 0.773 0.814 0.600 0.560
KMT2B – – 0.844 0.729 0.468
KMT2C – – – 0.650 0.464
KMT2D – – – – 0.458
KMT2E – – – – –
PCa, prostate cancer; Spearman correlation; P!0.001 for all comparisons.Chi et al. 2010). Contrarily, concerning the enzymes that
have overlapping functions, the same trend was not
apparent. This is most likely due to function redundancy,
so that oncogenesis is already facilitated through the
alteration of a single enzyme responsible for a specific PTM
(Fullgrabe et al. 2011).
We found that H3K4 methyltransferase SMYD3 was
upregulated in PCa, paralleling previous observations
in colorectal, hepatocellular, and breast carcinomas
(Hamamoto et al. 2004, 2006), whereas KMT2 family
members (which accomplish the same PTM) were down-
regulated. Remarkably, higher SMYD3 transcript levels were
associated with locally advanced disease, suggesting an
associationwithmore aggressive PCa. Interestingly, SMYD3
overexpressionhas been linkedwith enhancedproliferation
and loss of differentiation (Hamamoto et al. 2006, Chen
et al. 2007,Wang et al. 2008, Zou et al. 2009, Ren et al. 2011)
and this may support the association found in PCa.
Moreover, SMYD3 also methylates H4K5 and H4K20 and
other non-histone proteins, which may also contribute
to its oncogenic role (Foreman et al. 2011, Van Aller et al.
2012). We found that KDM5A, encoding an H3K4
demethylase, was also overexpressed in our PCa series.
Remarkably, KDM5A has an antagonistic interaction with
pRB, and it is also associatedwithMYC (Rotili&Mai 2011), a
proto-oncogene which is upregulated in PCa. This putativeoncogenic activity, already demonstrated in gastric cancer
(Blair et al. 2011), is also supported by our findings.
On the other hand, nearly all members of the KMT2
family were globally downregulated in PCa. This family
also targets H3K4, but its downregulation might not
impact in H3K4me3 levels owing to SMYD3 overexpres-
sion. KMT2A and KMT2C displayed higher expression
levels in PCa cases with higher GS and more advanced
stage, although levels remained lower than those of NPTs.
KMT2s operate in complexes (Ansari & Mandal 2010),
a feature that may explain the observed correlation bet-
ween some members of this family. Because not all KMT2
genes are present in the same complexes, a downstream
mechanism responsible for their global downregulation
in prostate carcinogenesis likely exists. Furthermore,
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Figure 4
Performance of PRMT6 expression as biomarker for PCa. Receiver
operator characteristic (ROC) curve evaluating the ability of PRMT6
expression levels in discriminating PCa from normal prostate tissues.
AUC, area under the curve.
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Figure 5
Association of HMTs with clinicopathological parameters. Distribution of
SMYD3 (A) and KMT2A (B) expression levels according to pathological
stage, showing higher levels in locally advanced disease stage pT3ba negative crosstalk between methylation of H3R2 by
PRMT6 and H3K4 by KMT2 complex was described
(Guccione et al. 2007) and increased expression of PRMT6
was identified in our set of PCa. The overexpression of this
histone modifier, already reported in bladder and lung
cancer, might lead to a decrease in p53 levels, fostering
tumorigenesis (Yoshimatsu et al. 2011, Neault et al. 2012).
Interestingly, PRMT6 proved to be the HMT that best
discriminated PCa from NPTs, further supporting a role
for its deregulation in prostate carcinogenesis.
SUV39H2 and KDM4B methylate and demethylate
H3K9, respectively. SUV39H2’s role in cancer depends
on the model: in B-cell lymphomas it acts as a tumor
suppressor (Cloos et al. 2008), whereas in breast cancer it
is regarded as an oncogene (Franci et al. 2013), as our
results suggest for PCa. A positive correlation between
KDM4B expression and increased PCa grade has been
reported (Coffey et al. 2013), but we were not able to
confirm it, probably due to methodological differences.
Coffey et al. used samples of benign prostate hyperplasia
as controls and this lesion is reported to be potentially
linked with PCa arising in the transition zone (Guess
2001). Moreover, their analysis was based on a qualitative
evaluation of cytoplasmic immunostaining in a small
portion of tissue (Coffey et al. 2013). On the contrary,KM
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Figure 6
Kaplan–Meier estimated disease-free survival curves for PCa patients.
Disease-free survival curves of 136 PCa patients according to expression
levels of EZH2 (A) and SMYD3 (B). The results of RT-qPCR presented were
categorized using third quartile (75th percentile) value as the cutoff.
Table 4 Cox regression models assessing the potential of
clinical and epigenetic variables in the prediction of disease-
free survival for 136 PCa patients
Gene Variable HR
95% CI for
HR
P value
(CR)
EZH2 PSA levels O med 1.652 0.914–2.986 0.096
Gleason score 4.206 1.820–9.718 0.001
pT stageO2 0.148
vs 3a 1.457 0.753–2.819 0.264
vs 3b 2.397 0.980–5.864 0.055
EZH2 expression
O Q75
1.890 0.983–3.637 0.056
SMYD3 PSA levels O med 1.697 0.940–3.064 0.079
Gleason score 4.259 1.817–9.982 0.001
pT stage 2 0.086
vs 3a 1.476 0.755–2.886 0.255
vs 3b 2.662 1.115–6.356 0.027
SMYD3 expression
O Q75
2.049 1.096–3.832 0.025
PCa, prostate cancer; CR, Cox regression; HR, hazard ratio; Med, median value;
Q75, quartile 75 value; bold highlights statistical significance (P!0.05).we used morphologically NPT from the peripheral zone,
were over 80% of PCa originate, and expression was
quantitatively assessed at transcript level.
A major goal of our study was to determine the
potential clinical usefulness of altered HMTs and HDMs
expression in PCa. Only EZH2 and SMYD3 disclosed a
significant association with DFS, in univariate analysis.
Similar results have been reported for EZH2 expression,
although assessed by immunohistochemistry (Varambally
et al. 2002, Laitinen et al. 2008, Wolters et al. 2010), and
it was found to independently predict PCa recurrence.
Although we did not confirm this result for EZH2 at
transcript level, a statistical trend was apparent. It should
be recalled that our series only incorporates patients
with clinically localized PCa, submitted to radical pro-
statectomy, which represent a subset of the whole
spectrum of PCa patients. Because these patients are
selected for having clinically organ-confined disease, thecorresponding PCas are usually of low and intermediate
grade (mostly GS 6 and 7 in the biopsy) and low stage
(cT1c and cT2). Thus, it does not comprise the full
spectrum of PCa, as clinically advanced and high-grade
cases at diagnosis will not be considered (in general) for
curative-intent radical prostatectomy. Notwithstanding
these limitations, high SMYD3 expression retained prog-
nostic significance in multivariate analysis, confirming its
potential clinical usefulness. To more easily translate
for routine practice, however, it would be important to
determine if immunohistochemical assessment of SMYD3
expression would provide the same result. Though several
commercially available antibodies were tested, none
provided satisfactory results.
Concerning disease-specific survival, no statistically
significant associations were apparent, probably due to
relatively short follow-up data. A follow-up period of 15 or
20 years is usually required to detect differences in PCa
survival in patients with localized disease submitted to
radical prostatectomy (Popiolek et al. 2013). Nonetheless,
biochemical recurrence is also an important primary
endpoint in many studies. As expected, GS and patho-
logical stage were of prognostic significance in univariate
analysis, although only the former and stage pT3b
denoted independent prognostic value in multivariate
analysis. The fact that stage pT3a did not surfaced as
independent prognostic parameter for DFS in multivariate
analysis is most likely due to the association between
tumor stage and histological grade, as pT3a cancers were
mostly of high GS.
In conclusion, we identified a set of HMTs and HDMs
deregulated in PCa that might contribute to the disease
development and progression. To the best of our knowl-
edge, this is the first study to demonstrate that HMT SMYD3
expression levels are able to predict disease-specific survival
of PCa patients with clinically localized disease, submitted
to radical prostatectomy. Therefore, determination of
SMYD3 expression levels in prostate biopsies might be
able to convey relevant prognostic information in a pre-
therapeutic setting. Functional studies are mandatory to
ascertain the role of SMYD3 in prostate carcinogenesis.Supplementary data
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